The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation (Q37981983)

26 August 2017

title

The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation (English)

1 reference

26 August 2017

1 reference

ChEBI release 2020-05-28

Rathi N Pillai

1

1 reference

26 August 2017

Suresh S Ramalingam

series ordinal

2

1 reference

26 August 2017

publication date

1 April 2012

1 reference

26 August 2017

published in

Current Oncology Reports

1 reference

26 August 2017

volume

14

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

105-110

1 reference

The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

The anaplastic lymphoma kinase in the pathogenesis of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

A mouse model for EML4-ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

The biology and treatment of EML4-ALK non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0213-4

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22311682

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22311682

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22311682

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11912-012-0213-4

1 reference

26 August 2017

1 reference